← Back to headlines
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial
The company said more than 90% of patients started atirmociclib within three months of stopping their previous cancer medicine
18 Mar, 11:52 — 18 Mar, 11:52
